Text Size

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00084812
First received: June 10, 2004
Last updated: March 21, 2013
Last verified: March 2013
History of Changes
  Purpose

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Safingol may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of safingol when given with cisplatin in treating patients with locally advanced or metastatic solid tumors.


Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
 Drug: cisplatin
Drug: safingol
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Labeled, Non-Randomized Phase I Study of Safingol Administered With Cisplatin in Patients With Advanced Solid Tumors

Resource links provided by NLM:

MedlinePlus related topics: Cancer
Drug Information available for: Cisplatin
U.S. FDA Resources

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • Recommended phase II dose as assessed by NCI toxicity scale during 3-4 weeks of treatment [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Response as assessed by RECIST criteria during 3-6 weeks of treatment [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 43
Study Start Date: March 2004
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Safingol and Cisplatin

Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.

Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level.

 Drug: cisplatin Drug: safingol

Detailed Description:

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose (MTD) of safingol when administered with cisplatin in patients with locally advanced or metastatic solid tumors.

Secondary

  • Determine the toxic effects of this regimen in these patients.
  • Determine the clinical pharmacokinetics of this regimen in these patients.
  • Determine, preliminarily, the therapeutic activity of this regimen in these patients.
  • Determine a safe dose (i.e., near the MTD) for phase II evaluation of this regimen in these patients.
  • Determine, preliminarily, the role of ceramide and S1P, relative to response and apoptosis, in patients treated with this regimen.

OUTLINE: This is an open-label, non-randomized, dose-escalation study of safingol.

Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.

Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed solid tumor

    • Locally advanced or metastatic disease
  • Refractory to standard therapy OR not amenable to standard therapy
  • No known CNS metastasis or CNS primary

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • Karnofsky 70-100%

Life expectancy

  • At least 12 weeks

Hematopoietic

  • Neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • WBC count ≥ 3,500/mm^3
  • Hemoglobin ≥ 9.5 g/dL
  • Haptoglobin ≥ 30 mg/dL
  • No concurrent hemolysis or history of non-drug-induced hemolysis (e.g., spherocytosis)

Hepatic

  • AST and ALT ≤ 2.5 times upper limit of normal
  • Bilirubin ≤ 1.5 mg/dL
  • PT and PTT normal

Renal

  • Creatinine ≤ 1.5 mg/dL

Cardiovascular

  • No cardiac arrhythmias
  • No congestive heart failure
  • No myocardial infarction within the past 6 months

Other

  • Not pregnant
  • Negative pregnancy test
  • No nursing during and for at least 2 months after study participation
  • Fertile patients must use effective contraception during and for at least 2 months after study participation
  • HIV negative
  • No mental incapacity that would preclude giving informed consent
  • No moderate-to-severe high-frequency hearing loss
  • No persistent severe (grade 2) drug-induced peripheral neuropathy
  • No known allergy to cisplatin or any other platinum-containing compound
  • No serious or uncontrolled infection
  • No other medical condition or reason that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • At least 4 weeks since prior immunotherapy

Chemotherapy

  • Prior cisplatin allowed
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)

Endocrine therapy

  • Not specified

Radiotherapy

  • At least 4 weeks since prior radiotherapy

Surgery

  • Not specified

Other

  • Recovered from all prior therapy

  • No concurrent vitamins, antioxidants, herbal preparations, or supplements

    • Concurrent single tablet multivitamin allowed
  • No other concurrent investigational medications
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00084812

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Gary K. Schwartz, MD Memorial Sloan-Kettering Cancer Center
Principal Investigator: Archie N. Tse, MD, PhD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00084812     History of Changes
Other Study ID Numbers: 04-002, MSKCC-04002
Study First Received: June 10, 2004
Last Updated: March 21, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Memorial Sloan-Kettering Cancer Center:
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Neoplasms
Cisplatin
Safingol
Antineoplastic Agents
Therapeutic Uses
 Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 17, 2013